Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.
About Atara Biotherapeutics (ATRA)
Atara Biotherapeutics, Inc. is a pioneering biotechnology company dedicated to developing transformative therapies for patients suffering from serious diseases, including solid tumors, hematologic cancers, and autoimmune conditions. Founded in 2012, the company is named after Atara Ciechanover, whose battle with cancer inspired its mission to empower patients with innovative treatment options. Atara operates in the United States healthcare sector and focuses on advancing cellular immunotherapy platforms to address significant unmet medical needs.
Core Business Areas
Atara specializes in the development of allogeneic T-cell immunotherapies, leveraging groundbreaking research into the role of T-cells and growth factors such as activin and myostatin in disease progression. The company’s product pipeline is centered on addressing the underlying mechanisms of diseases, offering novel solutions for patients with limited or no effective treatment options. Atara’s key areas of focus include:
- Epstein-Barr Virus (EBV)-Targeted Therapies: Leveraging EBV-specific cytotoxic T lymphocytes (CTLs) to treat diseases associated with EBV, including post-transplant lymphoproliferative disease (PTLD).
- CAR-T Cell Therapy: Developing next-generation chimeric antigen receptor (CAR) T-cell therapies, such as ATA3219, to target hematologic malignancies.
- Multiple Sclerosis (MS) and Autoimmune Diseases: Investigating innovative therapies like ATA188 to address progressive forms of MS by targeting EBV-infected B-cells implicated in autoimmune pathogenesis.
Product Pipeline
Atara’s robust pipeline includes several promising product candidates designed to address critical gaps in current medical treatments:
- Tab-cel®: An allogeneic EBV-specific T-cell immunotherapy targeting EBV-associated cancers, currently in advanced clinical trials.
- ATA188: A groundbreaking therapy aimed at treating progressive multiple sclerosis by modulating immune responses to EBV-infected cells.
- ATA3219: A CAR-T platform designed to enhance the efficacy and safety of T-cell therapies for hematologic cancers.
These therapies reflect Atara’s commitment to addressing both rare and prevalent diseases through innovative approaches rooted in cellular biology and immunotherapy.
Collaborations and Research Partnerships
Atara’s strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK) underscores its commitment to advancing T-cell immunotherapy research. This partnership focuses on the development of three T-cell product candidates targeting EBV, cytomegalovirus (CMV), and Wilms Tumor 1 (WT1). By combining Atara’s expertise in immunotherapy with MSK’s research capabilities, the company aims to accelerate the development of groundbreaking treatments for cancer and other diseases.
Competitive Landscape
Atara operates in a highly competitive biotechnology landscape, with key competitors including companies specializing in CAR-T therapies, allogeneic cell therapies, and advanced biologics. However, Atara differentiates itself through its focus on allogeneic T-cell platforms, which offer potential advantages in scalability, manufacturing, and cost-effectiveness compared to autologous therapies. Additionally, its emphasis on EBV-targeted therapies positions it uniquely within the immunotherapy space, addressing both oncology and autoimmune indications.
Challenges and Opportunities
While Atara faces challenges such as navigating complex regulatory pathways, achieving clinical trial success, and competing in a crowded biotech market, it also has significant opportunities to establish itself as a leader in allogeneic immunotherapy. By addressing high unmet medical needs and leveraging its innovative pipeline, Atara has the potential to transform treatment paradigms for a range of serious diseases.
Conclusion
Atara Biotherapeutics is at the forefront of cellular immunotherapy, driven by a mission to empower patients with better treatment options. Through its innovative product pipeline, strategic collaborations, and focus on addressing unmet medical needs, Atara is poised to make a meaningful impact in the biotechnology industry. Its commitment to advancing science and improving patient outcomes underscores its significance as a key player in the healthcare sector.
Atara Biotherapeutics (Nasdaq: ATRA) announces the appointment of Ameet Mallik to its Board of Directors. Mr. Mallik, an expert in biotechnology with over 25 years of experience, has a successful history of bringing oncology therapeutics to market. His leadership is expected to enhance Atara's efforts to commercialize its lead product, tab-cel®, anticipated for approval in 2022. Mallik's expertise spans commercial operations at Novartis and Rafael Holdings, positioning him to drive Atara's mission of transforming the lives of patients with serious diseases.
Atara Biotherapeutics (Nasdaq:ATRA) announced the grant of 110,626 restricted stock units and stock options for 69,744 shares to newly hired employees. These awards were approved by the Compensation Committee under the 2018 Inducement Plan, effective August 2, 2021. The restricted stock units will vest over four years, with the first 25% vesting after one year. The stock options also vest over four years, starting with 25% after the first anniversary. This action complies with Nasdaq Listing Rule 5635(c)(4).
Atara Biotherapeutics announced it will release its second quarter 2021 financial results post-market on August 9, 2021. Following the release, a live conference call will be held at 4:30 p.m. EDT to discuss financial results and provide corporate updates. Participants can join by calling 877-407-8291 for domestic callers or 201-689-8345 for international. The company aims to provide transformative therapies using its EBV T-cell platform to address serious diseases.
Atara Biotherapeutics (Nasdaq: ATRA) has granted 124,580 restricted stock units and options to purchase 99,585 shares to newly hired employees as part of its 2018 Inducement Plan. The stock options have a ten-year term with an exercise price of $16.05 per share, aligning with the company's closing stock price on July 1, 2021. The awards support Atara’s strategy to attract talent in the competitive T-cell immunotherapy field, aimed at developing therapies for cancer and autoimmune diseases.
Atara Biotherapeutics (Nasdaq: ATRA) has joined the Rare Disease Company Coalition, focusing on developing treatments for rare diseases like EBV-driven post-transplant lymphoproliferative disease. This alliance of life sciences companies aims to inform policymakers about the unique challenges in rare disease therapies and advocate for supportive policies to enhance innovation and access to treatments. Atara is committed to addressing the urgent needs of patients with rare blood cancers and is actively engaging with industry peers to advance effective healthcare initiatives.
Atara Biotherapeutics (Nasdaq: ATRA) recently presented long-term overall survival (OS) data for its therapy, tabelecleucel (tab-cel), aimed at patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD). Presented at the American Transplant Congress 2021, the analysis from three clinical studies shows a 1-year and 2-year OS rate of 100% and 87.5%, respectively, in certain patient groups. Tab-cel was well tolerated, with no significant safety issues reported, addressing a critical need in treating this high-mortality condition.
Atara Biotherapeutics (Nasdaq: ATRA) announced the granting of 140,861 restricted stock units and stock options for 124,966 shares to newly hired employees, approved by the Compensation Committee. The awards are part of the 2018 Inducement Plan, with vesting periods spanning four years. The stock options have a ten-year term and an exercise price of $13.97, equal to the closing price on June 1, 2021. This information is provided in compliance with Nasdaq Listing Rule 5635(c)(4), highlighting Atara's commitment to attracting talent as it advances its T-cell immunotherapy platform.
Atara Biotherapeutics (Nasdaq: ATRA) has granted inducement awards to Cokey Nguyen, the new Senior VP and Chief Scientific Officer. The awards include 115,440 restricted stock units and stock options for 174,249 shares, part of the 2018 Inducement Plan, dated May 10, 2021. The restricted stock units will vest over four years, while stock options will have a ten-year term at an exercise price of $13.24 per share. This move adheres to Nasdaq Listing Rule 5635(c)(4), aimed at attracting key talent for the company's ongoing development in T-cell immunotherapy.
Atara Biotherapeutics (Nasdaq: ATRA) announced participation in the Cowen Virtual Oncology Innovation Summit on May 20, 2021, featuring CEO Pascal Touchon and CMO AJ Joshi. The discussion will focus on Atara's innovative T-cell immunotherapy platform aimed at treating serious conditions such as solid tumors and autoimmune diseases. A live webcast will be available on Atara's website, with an archived replay accessible for 30 days post-event. Atara is leading in T-cell immunotherapy development with a robust pipeline, including treatments for Epstein-Barr virus-driven diseases.
Atara Biotherapeutics (Nasdaq: ATRA) has appointed Dr. Cokey Nguyen as Chief Scientific Officer, enhancing its focus on T-cell immunotherapy. Dr. Nguyen brings extensive experience from leadership roles at Fate Therapeutics and Pfizer, specializing in oncology and cell therapy. His expertise aims to accelerate Atara's pipeline, which includes therapies for EBV-related diseases and multiple sclerosis. Atara's ongoing commitment to innovation is highlighted as they expand their allogeneic EBV T-cell platform, with a goal of providing transformative treatments for patients with unmet medical needs.
FAQ
What is the current stock price of Atara Biotherape (ATRA)?
What is the market cap of Atara Biotherape (ATRA)?
What does Atara Biotherapeutics specialize in?
What is the focus of Atara’s product pipeline?
How does Atara differentiate itself from competitors?
What are Atara’s key collaborations?
What challenges does Atara Biotherapeutics face?
What is Tab-cel®?
What is ATA188, and what does it treat?
What diseases does Atara aim to address?
